Neurotrophic Keratitis Treatment Market Opportunities and Strategies to 2034

This report describes and explains the neurotrophic keratitis treatment market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global neurotrophic keratitis treatment market reached a value of nearly $1.07 billion in 2024, having grown at a compound annual growth rate (CAGR) of 27.93% since 2019. The market is expected to grow from $1.07 billion in 2024 to $4.99 billion in 2029 at a rate of 35.96%. The market is then expected to grow at a CAGR of 35.25% from 2029 and reach $22.6 billion in 2034.

Growth in the historic period resulted from high prevalence of diabetes, poor nutritional habits affecting overall eye health, increased focus on personalized medicine and strong economic growth in emerging markets. Factors that negatively affected growth in the historic period was low healthcare access in developing countries.

Going forward, increasing aging population worldwide, rising healthcare expenditure, rising prevalence of eye diseases and rise in ophthalmic surgeries will drive the growth. Factor that could hinder the growth of the neurotrophic keratitis treatment market in the future include limited availability of skilled professionals.

The global neurotrophic keratitis treatment market is highly concentrated, with large player dominating the market. The top 1 competitor in the market made up 100% of the total market in 2023. Dompé Farmaceutici S.p.A. holds 100.00% share of the market. (Note: Dompé Farmaceutici S.p.A. has recently launched a product and other companies has not yet generated revenue in the market, as its products are still in the development stage.)

Western Europe was the largest region in the neurotrophic keratitis treatment market, accounting for 47.30% or $508.5 million of the total in 2024. It was followed by North America, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the neurotrophic keratitis treatment market will be Asia Pacific and North America where growth will be at CAGRs of 43.78% and 38.78% respectively. These will be followed by Eastern Europe and Western Europe where the markets are expected to grow at CAGRs of 29.16% and 27.95% respectively.

The neurotrophic keratitis treatment market is segmented by treatment into topical antibiotics, recombinant human nerve growth factor (rhNGF), amniotic membrane transplantation, keratoplasty and other treatments. The recombinant human nerve growth factor (rhNGF) market was the largest segment of the neurotrophic keratitis treatment market segmented by treatment, accounting for 100% or $1.07 billion of the total in 2024. Going forward, the recombinant human nerve growth factor (rhNGF) segment is expected to be the fastest growing segment in the neurotrophic keratitis treatment market segmented by treatment, at a CAGR of 33.60% during 2024-2029.

The neurotrophic keratitis treatment market is segmented by route of administration into oral, topical and other routes of administration. The topical market was the largest segment of the neurotrophic keratitis treatment market segmented by route of administration, accounting for 100% or $1.07 billion of the total in 2024. Going forward, the topical segment is expected to be the fastest growing segment in the neurotrophic keratitis treatment market segmented by route of administration, at a CAGR of 34.18% during 2024-2029.

The neurotrophic keratitis treatment market is segmented by end-user into hospitals, homecare, specialty clinics and other end-users. The hospitals market was the largest segment of the neurotrophic keratitis treatment market segmented by end user, accounting for 47.31% or $508.59 million of the total in 2024. Going forward, the homecare segment is expected to be the fastest growing segment in the neurotrophic keratitis treatment market segmented by end user, at a CAGR of 46.25% during 2024-2029.

The top opportunities in the neurotrophic keratitis treatment market segmented by treatment will arise in the recombinant human nerve growth factor (rhngf) segment, which will gain $3.5 billion of global annual sales by 2029. The top opportunities in the neurotrophic keratitis treatment market segmented by route of administration will arise in the topical segment, which will gain $3.6 billion of global annual sales by 2029. The top opportunities in the neurotrophic keratitis treatment market segmented by end user will arise in the hospitals segment, which will gain $1.38 billion of global annual sales by 2029. The neurotrophic keratitis treatment market size will gain the most in the USA at $1.09 billion.

Market-trend-based strategies for the neurotrophic keratitis treatment market include focus on revolutionizing keratoconus treatment with contoured corneal tissue segments, advancing innovative cell therapies, offering new hope for patients with bullous keratopathy and developing research collaboration leads to Canada’s first preloaded descemet membrane endothelial keratoplasty transplant.

Player-adopted strategies in the neurotrophic keratitis treatment market include focus on strategic distribution agreements to enhance global access to its innovative therapies, focus on novel therapeutic advancements for developing novel therapies targeting rare ophthalmic conditions, offering regulatory benefits to accelerate research and commercialization and bezafibrate for the treatment of neurotrophic keratitis treatment (PBC) and focus on advancing gene therapy approaches for improving corneal healing in neurotrophic keratopathy treatment.

To take advantage of the opportunities, the analyst recommends the neurotrophic keratitis companies to focus on personalized treatment solutions for neurotrophic keratitis, focus on advancing innovative cell therapies for neurotrophic keratitis, focus on advancing research collaborations and simplifying treatment procedures, focus on recombinant human nerve growth factor (rhngf) market segment, expand in emerging markets, continue to focus on developed markets, focus on expanding distribution channels for neurotrophic keratitis treatment, focus on pricing strategy for neurotrophic keratitis treatments, focus on specialist outreach and education-driven promotion, focus on digital platforms and patient engagement tools, focus on strengthening patient engagement and education in homecare.

Major Market Trends

• Revolutionizing Keratoconus Treatment With Contoured Corneal Tissue Segments
• Innovative Cell Therapy Brings New Hope to Bullous Keratopathy Patients
• Research Collaboration Leads to Canada’s First Preloaded DMEK Transplant